META-ANALYSIS


Prognostic Value of Long Non-coding RNAs in Urological Malignancies: A Systematic Review, and Meta-Analysis



Zeinab Bagheri1, Mohammad-Hassan Arjmand2, 3, *
iD

1 Deputy of Research and Technology, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

Article Information


Identifiers and Pagination:

Year: 2021
Volume: 11
First Page: 115
Last Page: 125
Publisher ID: TOBIOMJ-11-115
DOI: 10.2174/1875318302111010115

Article History:

Received Date: 20/5/2021
Revision Received Date: 7/7/2021
Acceptance Date: 15/7/2021
Electronic publication date: 20/12/2021
Collection year: 2021

Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1560
Abstract HTML Views: 744
PDF Downloads: 408
ePub Downloads: 311
Total Views/Downloads: 3023
Unique Statistics:

Full-Text HTML Views: 540
Abstract HTML Views: 343
PDF Downloads: 263
ePub Downloads: 172
Total Views/Downloads: 1318



Creative Commons License
© 2021 Bagheri and Arjmand

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Postal code; 8815764646, Iran; Fax: 038 3334 9113; E-mails: Arjmandmh1@gmail.com; Arjmand.m@skums.ac.ir


Abstract

Background:

Many studies have explored the potential roles of long non-coding RNAs (lncRNAs) in urological cancer (UC) progression. The clinical outcome and prognosis of UCs remain weak. Therefore, finding clinical prognostic markers is needed to improve therapeutic potential. The aim of this study was to consider the possible association between the lncRNAs expression with the survival time and clinical outcomes in patients with UC.

Methods:

A literature search was performed in several related databases to find eligible English papers published before 9 February 2021. Hazard ratios (HRs) with 95% CI were calculated to investigate the association between lncRNAs expression and overall survival in patients with UC.

Results:

A total of 46 studies, including 39 lncRNAs were identified. Results indicated that lncRNAs expression was significantly correlated with poor overall survival (OS) outcome in patients with UCs (HR: 1.923, 95% CI: 1.448-2.554, P<0.001). Also, we divided included studies into up-regulated and down-regulated subgroups according to lncRNAs expression. The results indicated a significant association with poor OS outcomes in both up-regulated (HR=2.546, 95% CI: 1.896-3.41, P<0.001) and down-regulated (HR=0.33, 95% CI: 0.22-0.49, P<0.001). Moreover, expression of lncRNAs was significantly associated with lymph node metastasis (LNM) (OR=0.25, 95% CI: 0.13-0.47, P<0.001)

Conclusion:

Abnormal expression of various lncRNAs is a potential novel marker for predicting the clinical outcomes of urological tumors.

Keywords: Long non-coding RNAs, Urological cancer, Prognosis, Meta-analysis, Diagnosis, Urological tumors.